{"name":"Estrella Biopharma, Inc.","slug":"estrella-biopharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxOb3ZQeUc1b2NtaWhWZGJ5WnNqSmJpVXh5TUZJZkhxMTBYcTZtMktwd1AtbXNEcnd1Yi1rM2ZsNldEekZ1MWoxcXNRYUtxbU1Ld0tzeWJ2OUdYdkVnUTdrZURrS2pUNy1PcGswbHlpVWUyNk1DZ08xVG5CSG9MNzlDa2lOVlMtRW54dnU4ZmVqMF9ZaDNQekJRRmVYQ28zU1hTaklOaUd1XzBxVjJpS1kyT18wMG93MmJUeG1JWEdacXUxRGV5cEdHWmJZeV9DYUp4a2RSaFRreGZBc0pJaW02eGZVMnlBTVh1WHVOdHNDeGdpd3laTGc5TWlOQ0psSlFvdWl3TkphVFBoSzR6ZkN0YzZTSlZrcGM?oc=5","date":"2026-03-23","type":"pipeline","source":"businesswire.com","summary":"Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research - businesswire.com","headline":"Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Smal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxON1F5c2VTSHUtQlZGTjRDSXc0eExDbnloUGYyeTIwajBhTlpDbFNhaGJVb0VOenZnRFVNVl81azZUcDBxQUlHRHh2dnJUOHRaaDJGRXBQT0F1VTBWQTgwQURjU2xfdzhxRTFvcEtTNENpaFRUai1xdEhnbml3M0k2UTQ1VWYtZXhQcG5xVG1zaDJOa3lWbnNwdEdB?oc=5","date":"2026-02-09","type":"trial","source":"Yahoo Finance","summary":"Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR® - Yahoo Finance","headline":"Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxOcE92QWhRbTVnQmdiYzl2Mlp2VHl6a1ZJbkdXQl9zVXJrSm5xOU9YemFkUjMwOHJJckdGVkhCOXhDdDNKdEVtSHVULUt2MHZiOGlTTm8xMi0yTlR0N1Z6RVdrM1ZfcE1xQTlZbllhU3hrZl9zRFhfQW1vOVNodVdaS0o4Y2M3Mm9BSjFrWUdaXzFHVElKNS1sR3NmTlRyQ3JWZEFQcDNYeXlxY2JJWWtna0JqM2lOWTNHVlROMGxzdmZDZ1FfcEpzTW9NVGEyUmhNak0tOG9BZlBPMjdPWHlDTlpkajJwOUtDYTZLSFlScFhMOU1jY1BsLWhmVG9ISkdQMnJLYXdZR2lxV3doU21ZdjZJZ3RRcEt0TVlfRS1ONUxMSGVVRUNyRjBB?oc=5","date":"2026-02-03","type":"trial","source":"businesswire.com","summary":"Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR® - businesswire.com","headline":"Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQMXRyLTFzNXktV2gwQVQtemZ3RWkwemtjZ2dsVW9aekx3ZGs3U1Vxd0RkcUxmdmlKYzlXc1ZHdlBfb25oekZZbTZJRHZiTnZSMHNKeVh3d1YzcnA2a2VQcWtkZ2kzN1VRMlZxbGZ0VXBVTWdxYTc3elVNMWtHUUJxam5OOWphTE11ZUhDa0lFMkFEeWtEVV9aLXpRMzVibWJJOW91V1FqYXpac1pQbnlQYjItQVZBUTE3eGI1ek9JSlV6S1JQSDg0b3NzaHpuYnRjX3JSZmhHSDBTS0U2OVE?oc=5","date":"2025-12-04","type":"trial","source":"businesswire.com","summary":"Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation - businesswire.com","headline":"Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPbG5Leng2d09EM1c4YjNkQXNXbVUwRVpSbTh0empOMGF2THFPam1fNmlGX1Q0RFZ0b3FyQm5wUUpxNG1Yc2MtRmUtX2ZKZTlNZVAyMnhaQkVQUWxDa3AxWkFPenBFd3VHRm53YTA0SjlBS29XUndRRkZHaDMxNG9rN0E4YWM0aktZeldsc2s3RVZXQktObTgydlRCUHhQZXE0T2Vwc2hONWh5RmxkSFBPNm9ZaE1OejBGNGxCdnFmMkliYXl1NWZfNkZn?oc=5","date":"2025-10-06","type":"pipeline","source":"businesswire.com","summary":"Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements - businesswire.com","headline":"Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxOR3hlYkxWaVpPeUhiTUh1RWx5N3pySm9aX09HcEhJTFd6d2EyUVo1YUxnckxUWE92S3RtbjNfYkRhVkVWbWlLM2p3Y3lTSVg0UGVmNkZlTWtzemtUZkRqUTR3YUpaSUZtd2FnRnFZOVVZbHVuemlKMFY3d3RaSjk3dXNtalBsbTdXRkpGWF9zZG05b3BHQWU0enRKSjhheHVsSXZqbUZReDZRWTBNeHVyYmJHNWd5UXE1dGNvX2xZYno2SFMxTWpfcmtWYnU3ZVVESV9rcEhtZUE1N2picTlBRWVWQXE2NURFRzNn?oc=5","date":"2024-10-03","type":"trial","source":"CGTLive®","summary":"First Patient Dosed Achieves Complete Response in Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas - CGTLive®","headline":"First Patient Dosed Achieves Complete Response in Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 i","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPeFlwQUhfd3VPWS1VU0VWbGowZnFYZDA4T1h6Uk1ucGtqd2Y0cVZ2T3doRmQwd2FEM1JWMUNESVN5OFFWRndKaG1PeXloODBkdjNmNEthTVhITkdZR2dtajJZSmptVVI1OXFYdTEwUnZNMl81LTgtQlI1X2RkcHE3ZHdNaHR4eFlaUEJrVUNmbFhXMHM4OWp2TktweFFMNEJWSXE2RVdUNlBFaUQwVTVfZng1M0dZaFdvSFdBd29OOHVtdXJFZVJVb2ZnSlp6ZFdfRWxVUHlSbHZCUG9kXzF5d01xY3NkRUk?oc=5","date":"2024-09-27","type":"pipeline","source":"BioSpace","summary":"Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells - BioSpace","headline":"Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxPd3ZicWNIbXJkZGhETXYyRmxkSjFNVWRoSzVNZFZKUWtpNUkyQ3JYMzRDZEJidklCQlhyNGJhV2c3cVJyRkdqQ1p2UWFGVW84NmphNG9waTBoRjRmMm0yRUtlMldLdzVtRjBHOUExajBYMS1tRnducG1fbEFuNDIxcV9vMWNZeTU0cE5ZLUU0S3BHTnB2cHRGNUc1Q2hrQ3JDemJCOGNFU3JTZ0pvVUhPeTVSTmZ1MXdHZ3NlVjZYaEdCWFdfR05hbUxFNGtkdFRiTHdxclFMYmFnZjJCTjE5NA?oc=5","date":"2023-03-09","type":"regulatory","source":"BioPharma APAC","summary":"Estrella Biopharma's ARTEMIS® T Cell Therapy EB103 IND Cleared by FDA for B-Cell Lymphomas Clinical Trial - BioPharma APAC","headline":"Estrella Biopharma's ARTEMIS® T Cell Therapy EB103 IND Cleared by FDA for B-Cell Lymphomas Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPX21veXMzUXBoekFhT3F6OWtZQ01CVnAtMVZuVlJMakFyUUFwVlZLdERiSUZZNDZ2OGxsYVhyWlBwRGpobWNsTnZHc0NjcS1xc2FjVVN0bWRURkg2RTNrVWxXU01mbVY3QjFBakxqM3V6X3BLS2QyQkp0bGw1bmQxSGNHV2xzNHdETDJZc3F1aWxBOEJKVklUTDlNdw?oc=5","date":"2022-10-03","type":"pipeline","source":"Labiotech.eu","summary":"Estrella and TradeUP merge to become publicly traded company - Labiotech.eu","headline":"Estrella and TradeUP merge to become publicly traded company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPVmNyVWhQZzdVb3BhaDhiR2pSZDMtS1RBYmt0Z2NmTU1mUVVsOFpYYlR6VXlXc3dTa3JCLW54QmtmUHRGVWQ1X2RaTm0xdjRKa0xuM3E3cEVMSHkwODBNVG5mUUtXUnNxdXFlN2h6alNTTm16NkNMdWRfT2g3MUtYVU1mWmx2aElYSXI0Vkd3VERvUWNUTk9QNEE2MklxY0pmdmtIMmdzMGY0VEpIUGhmbkdDeXlvaDdfbGpWNHZYYWpGUQ?oc=5","date":"2022-10-03","type":"pipeline","source":"Fierce Biotech","summary":"SPAC on track: Preclinical T-cell company Estrella latest in string of biotechs to take blank check route - Fierce Biotech","headline":"SPAC on track: Preclinical T-cell company Estrella latest in string of biotechs to take blank check route","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}